DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2258355/at-t-t-q1-earnings-on-the-horizon-analysts-insights-on-key-performance-measures?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2258355 Apr 19, 2024 - Beyond analysts' top -and-bottom-line estimates for AT&T (T), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024. 0

https://www.zacks.com/stock/news/2260540/at-t-t-vs-t-mobile-tmus-which-stock-wins-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2260540 Apr 23, 2024 - TMUS appears to be a better pick now compared to T, given the solid EPS growth in recent quarters, greater 5G coverage and robust demand for postpaid services. 0

https://www.fool.com/earnings/call-transcripts/2024/04/25/t-mobile-us-tmus-q1-2024-earnings-call-transcript/?source=iedfolrf0000001 Apr 25, 2024 - TMUS earnings call for the period ending March 31, 2024. 0

https://www.zacks.com/stock/news/2262911/t-mobile-tmus-q1-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2262911 Apr 25, 2024 - Although the revenue and EPS for T-Mobile (TMUS) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.denverpost.com/2024/04/24/tiktok-has-promised-to-sue-over-the-potential-us-ban-whats-the-legal-outlook/ Apr 24, 2024 - Legislation forcing TikTok’s parent company to sell the video-sharing platform or face a ban in the U.S. has received President Joe Biden’s official signoff. But the newly minted law could face an uphill battle in court. Critics of the sell-or-be-banned ultimatum argue that it violates TikTok users’ First Amendment rights. The app’s China-based owner, ByteDance, has already promised to sue, calling the legislation unconstitutional. Whether a court challenge could successfully block a potential TikTok ban treads into murky waters. The law’s opponents, which include advocacy organizations like the American Civil Liberties Union, maintain that the government hasn’t come close to justifying such action — while others say that national-security claims could still prevail. 0

https://www.zacks.com/stock/news/2263203/t-rowe-trow-q1-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2263203 Apr 26, 2024 - Although the revenue and EPS for T. Rowe (TROW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2263526/t-rowe-price-trow-q1-earnings-beat-estimates-aum-rises-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2263526 Apr 26, 2024 - T. Rowe Price's (TROW) Q1 earnings beat estimates on increased net revenues, an improvement in AUM and a decline in expenses. A rise in cash and cash equivalents will help it continue investing. 0

https://seekingalpha.com/article/4687059-t-bills-gold-and-macro-volatility?source=feed_tag_wall_st_breakfast Apr 27, 2024 - Amrita Roy and Rob Isbitts are both bullish on gold and T-bills. Inflationary and deflationary tug of war and macro volatility. 0

https://www.zacks.com/stock/news/2273949/want-better-returns-don-t-ignore-these-2-computer-and-technology-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2273949 May 15, 2024 - Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. 0

https://www.zacks.com/stock/news/2275579/amgen-s-amgn-tarlatamab-receives-fda-approval-for-sclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2275579 May 17, 2024 - Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells. 0